MARAVAI LIFESCIENCES HOLDINGS, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 32/100
What the filing says
Maravai reported Q2 2026 revenue of $51.4M (up 8.5% YoY), net loss of $21.6M, and Adjusted EBITDA of $8.7M. Full-year Adjusted EBITDA guidance raised to $33–35M (from $30–32M prior); revenue guidance reiterated at $205–215M. TriLink segment grew 11.5% YoY; Cygnus grew 2.8%. Key milestone: opened GMP enzyme manufacturing facility; ModTail product line reached 125 active customers in one year.
Why this rating
Modest revenue growth (8.5% Q2, 24.4% H1 driven partly by $14.3M COVID vaccine CleanCap orders). Adjusted EBITDA guidance raise meaningful but base business shows slowing demand post-COVID surge. At $300M market cap, improvements are real but incremental.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.